Glenmark launches RYALTRIS® in Brazil for respiratory treatment
Glenmark launches RYALTRIS® in Brazil for respiratory treatment. The launch marks Glenmark's expanded footprint in the global respiratory market. RYALTRIS® is a combination therapy for asthma and COPD. This strategic move strengthens its presence in Latin America.
📊 STOCKS: $GLENMARK | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #Launch
This brief is AI-generated from public news sources for informational purposes only. Not investment advice. Always consult a SEBI-registered advisor before trading.